# Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

> **NCT01982630** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 87 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** MK-8521
- **DRUG:** Liraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01982630
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-07
- **Primary completion:** 2014-10-03
- **Final completion:** 2014-10-03
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01982630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01982630, "Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01982630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*